Like many employers, they wanted to know: What is the real impact of GLP-1s on diabetes? Specifically, they want to understand whether the investment in GLP-1s has been effective in a) helping their diabetic population of nearly 3,000 employees and members better manage their chronic disease and b) addressing the $40M+ in annual spend for this population
Larsson LI, Holst J, Hakanson R, and Sundler F
Troglitazone has several recognized therapeutic properties as a hypoglycemic agent, an antioxidant, a vasodilator agent, an anticonvulsant, an anticoagulant, a platelet aggregation inhibitor, an antineoplastic agent, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor and a ferroptosis inhibitor (National Center for Biotechnology Information, 2023h)
Levit has used a modification of the ABCD rule developed for detection of suspicious pigmented lesions on the skin and applied it to the nail unit [39]